Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Peintinger, F; Buzdar, AU; Kuerer, HM; Mejia, JA; Hatzis, C; Gonzalez-Angulo, AM; Pusztai, L; Esteva, FJ; Dawood, SS; Green, MC; Hortobagyi, GN; Symmans, WF.
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Ann Oncol. 2008; 19(12): 2020-2025.
Doi: 10.1093/annonc/mdn427
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Peintinger Florentia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: The aim of this study was to compare the extent of pathologic response in patients with HER2-positive (HER2+) breast cancer treated with standard neoadjuvant chemotherapy, with or without trastuzumab (H), according to hormone receptor (HR) status. Patients and methods: We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C). Residual cancer burden (RCB) was determined from pathologic review of the primary tumor and lymph nodes and was classified as pathologic complete response (pCR) or minimal (RCB-I), moderate (RCB-II), or extensive (RCB-III) residual disease. Results: In HR-positive (HR+) cancers, a higher rate of pathologic response (pCR/RCB-I) was observed with concurrent H + 3-wP/FEC (73%) than with 3-wP/FEC (34%, P = 0.002) or wP/FAC (47%; P = 0.02) chemotherapy alone. In HR-negative (HR-) cancers, there were no significant differences in the rate of pathologic response (pCR/RCB-I) from 3-wP/FAC (50%), wP/FAC (68%), or concurrent H + 3-wP/FEC (72%). Conclusions: Patients with HR+/HER2+ breast cancer obtained significant benefit from addition of trastuzumab to P/FEC chemotherapy; pathologic response rate was similar to that seen in HR-/HER2+ breast cancers.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antibodies, Monoclonal - administration & dosage
- Antibodies, Monoclonal, Humanized -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology
- Clinical Trials as Topic -
- Cyclophosphamide - administration & dosage
- Doxorubicin -
- Epirubicin - administration & dosage
- Female -
- Fluorouracil - administration & dosage
- Humans -
- Middle Aged -
- Neoadjuvant Therapy -
- Neoplasm, Residual - prevention & control
- Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - genetics Neoplasms, Hormone-Dependent - pathology
- Paclitaxel - administration & dosage
- Randomized Controlled Trials as Topic -
- Receptor, erbB-2 - biosynthesis Receptor, erbB-2 - genetics
- Receptors, Estrogen - metabolism
- Receptors, Progesterone - metabolism